secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-06-23T21:19:36+00:00
Accession:  0001193125-26-279788
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics appoints Robert Azelby to board; receives option for 35,910 shares at $27.97
--------------------------------------------------------------------------------

- Board expanded to seven directors; Azelby fills newly created vacancy as Class II director term expiring 2029.
- Azelby is independent; will serve on Compensation and Nominating/Corporate Governance committees.
- Receives equity: option to purchase 35,910 shares at $27.97, plus RSU for 5,740 shares, vesting over 3 years.
- Annual retainer of $45,000 for board service plus committee retainers of $7,500 and $5,000.
- Azelby brings 30+ years biopharma experience including Juno and Amgen; company advancing vopimetostat for pancreatic cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/0001193125-26-279788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/d79260d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-279788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer